UniProt ID | ELOC_HUMAN | |
---|---|---|
UniProt AC | Q15369 | |
Protein Name | Elongin-C | |
Gene Name | ELOC {ECO:0000312|HGNC:HGNC:11617} | |
Organism | Homo sapiens (Human). | |
Sequence Length | 112 | |
Subcellular Localization | Nucleus . | |
Protein Description | SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex). [PubMed: 7821821 In embryonic stem cells, the elongin BC complex is recruited by EPOP to Polycomb group (PcG) target genes in order generate genomic region that display both active and repressive chromatin properties, an important feature of pluripotent stem cells (By similarity; The elongin BC complex seems to be involved as an adapter protein in the proteasomal degradation of target proteins via different E3 ubiquitin ligase complexes, including the von Hippel-Lindau ubiquitination complex CBC(VHL By binding to BC-box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes.] | |
Protein Sequence | MDGEEKTYGGCEGPDAMYVKLISSDGHEFIVKREHALTSGTIKAMLSGPGQFAENETNEVNFREIPSHVLSKVCMYFTYKVRYTNSSTEIPEFPIAPEIALELLMAANFLDC | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
6 | Ubiquitination | --MDGEEKTYGGCEG --CCCCCCCCCCCCC | 42.62 | - | |
7 | Phosphorylation | -MDGEEKTYGGCEGP -CCCCCCCCCCCCCC | 30.58 | 27642862 | |
8 | Phosphorylation | MDGEEKTYGGCEGPD CCCCCCCCCCCCCCC | 23.69 | 29496907 | |
11 | S-nitrosocysteine | EEKTYGGCEGPDAMY CCCCCCCCCCCCEEE | 4.79 | - | |
11 | S-nitrosylation | EEKTYGGCEGPDAMY CCCCCCCCCCCCEEE | 4.79 | 19483679 | |
11 | Glutathionylation | EEKTYGGCEGPDAMY CCCCCCCCCCCCEEE | 4.79 | 22555962 | |
16 | Ubiquitination | GGCEGPDAMYVKLIS CCCCCCCEEEEEEEC | 8.37 | 19608861 | |
16 | Acetylation | GGCEGPDAMYVKLIS CCCCCCCEEEEEEEC | 8.37 | 19608861 | |
17 | Sulfoxidation | GCEGPDAMYVKLISS CCCCCCEEEEEEECC | 5.28 | 30846556 | |
18 | Phosphorylation | CEGPDAMYVKLISSD CCCCCEEEEEEECCC | 8.99 | 22817900 | |
20 | Acetylation | GPDAMYVKLISSDGH CCCEEEEEEECCCCC | 23.71 | 27452117 | |
20 | Ubiquitination | GPDAMYVKLISSDGH CCCEEEEEEECCCCC | 23.71 | - | |
24 | Phosphorylation | MYVKLISSDGHEFIV EEEEEECCCCCEEEE | 40.39 | - | |
32 | Sumoylation | DGHEFIVKREHALTS CCCEEEEECCEEECC | 47.45 | 19608861 | |
32 | Ubiquitination | DGHEFIVKREHALTS CCCEEEEECCEEECC | 47.45 | 21906983 | |
32 | Sumoylation | DGHEFIVKREHALTS CCCEEEEECCEEECC | 47.45 | - | |
32 | Acetylation | DGHEFIVKREHALTS CCCEEEEECCEEECC | 47.45 | 23749302 | |
38 | Phosphorylation | VKREHALTSGTIKAM EECCEEECCCCHHHH | 26.37 | 23911959 | |
39 | Phosphorylation | KREHALTSGTIKAML ECCEEECCCCHHHHH | 34.49 | 20860994 | |
43 | Ubiquitination | ALTSGTIKAMLSGPG EECCCCHHHHHCCCC | 27.81 | 21890473 | |
45 | Sulfoxidation | TSGTIKAMLSGPGQF CCCCHHHHHCCCCCC | 2.32 | 21406390 | |
47 | Phosphorylation | GTIKAMLSGPGQFAE CCHHHHHCCCCCCCC | 29.83 | - | |
67 | Phosphorylation | VNFREIPSHVLSKVC CCHHHCCHHHHHHHH | 31.71 | 20068231 | |
71 | Phosphorylation | EIPSHVLSKVCMYFT HCCHHHHHHHHHHEE | 23.19 | 20068231 | |
72 | Acetylation | IPSHVLSKVCMYFTY CCHHHHHHHHHHEEE | 34.98 | 30592871 | |
72 | Ubiquitination | IPSHVLSKVCMYFTY CCHHHHHHHHHHEEE | 34.98 | - | |
80 | Acetylation | VCMYFTYKVRYTNSS HHHHEEEEEEECCCC | 19.71 | 26051181 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of ELOC_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ELOC_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ELOC_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-32, AND MASS SPECTROMETRY. |